WEBULL
News
HMTXF
0.070
NaN%
--
Hemostemix Closes $480,000 Private Placement at $0.12 per Share
Newsfile · 12/31/2025 19:38
Hemostemix Appoints Dr. David B. Alper to Lead Physician Education and Join Scientific Advisory Board
Reuters · 12/23/2025 14:11
Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01
Newsfile · 12/23/2025 14:10
Hemostemix Showcases Breakthrough Wound Healing Therapy at Innovations in Wound Care Conference
Reuters · 12/18/2025 16:11
Hemostemix Hosts Florida Webinar Showcasing Autologous Stem Cell Therapy for CLTI
Reuters · 12/18/2025 16:11
Hemostemix Inc. Launches Phase I Clinical Trial of ACP-01 for Vascular Dementia
Reuters · 12/18/2025 16:05
Hemostemix Showcases Regenerative Advances at Innovations in Wound Healing 2025
Reuters · 12/18/2025 15:54
Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv)
Newsfile · 12/11/2025 14:40
Hemostemix Grants 963,000 Stock Options to Directors, Officers, Employees, and Consultants
Reuters · 12/11/2025 13:57
Hemostemix Grants Stock Options
Newsfile · 12/11/2025 13:57
Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000
Newsfile · 12/10/2025 16:17
Hemostemix Appoints Shaune Harding as Director of Patient Care and Clinical Operations
Reuters · 12/04/2025 14:10
Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations
Newsfile · 12/04/2025 14:10
Hemostemix Showcases Regenerative Advances at Innovations in Wound Healing 2025
Reuters · 12/03/2025 19:05
Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14
Newsfile · 12/03/2025 19:05
Hemostemix Announces $518,440 Private Placement Approved by TSXV
Reuters · 12/03/2025 16:31
Hemostemix to Attend DFCon San Antonio and Closed its Private Placement
Newsfile · 12/02/2025 14:10
Hemostemix Acquires Two Cardiology Practices in Dominican Republic
Reuters · 11/26/2025 21:21
Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two
Newsfile · 11/26/2025 21:21
Dr. William R. Shankle to Advance ACP-01 as a Treatment for Vascular Dementia
Newsfile · 11/20/2025 14:00
More
Webull provides a variety of real-time HMTXF stock news. You can receive the latest news about Hemostemix through multiple platforms. This information may help you make smarter investment decisions.
About HMTXF
Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patient’s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.